Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
26 déc. 2023 08h30 HE
|
Atreca, Inc.
CAMPBELL, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (“Atreca”) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery...
Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives
14 nov. 2023 16h30 HE
|
Atreca, Inc.
SAN CARLOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...
Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross
21 sept. 2023 08h00 HE
|
Atreca, Inc.
SAN CARLOS, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a...
Atreca Reports Second Quarter 2023 Financial Results and Announces Corporate Restructuring
10 août 2023 16h05 HE
|
Atreca, Inc.
Suspending development of ATRC-101 Cost-saving measures include 40% workforce reduction Focusing on advancing earlier stage ADC candidates and preserving discovery capabilities SAN CARLOS, Calif.,...
Atreca Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors during Oral Abstract Session at the ASCO 2023 Annual Meeting
05 juin 2023 08h00 HE
|
Atreca, Inc.
Clinical activity observed in multiple tumor types; longer progression-free survival observed in patients with high target expression; ATRC-101 continues to be well-tolerated Phase 2 go/no-go...
Atreca Reports First Quarter 2023 Financial Results and Recent Corporate Developments
10 mai 2023 16h05 HE
|
Atreca, Inc.
SAN CARLOS, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...
Atreca Announces Oral Presentation of ATRC-101 Phase 1b Study Data at ASCO 2023 Annual Meeting
26 avr. 2023 16h05 HE
|
Atreca, Inc.
SAN CARLOS, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel cancer therapeutics generated through...
Atreca to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
13 avr. 2023 08h00 HE
|
Atreca, Inc.
SAN CARLOS, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a...
Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data Update
29 mars 2023 16h05 HE
|
Atreca, Inc.
ATRC-101 continues to be well tolerated in ongoing Phase 1b trial; clinical activity observed in multiple tumor types; longer progression free survival observed in patients with high target expression...
Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023
23 mars 2023 17h00 HE
|
Atreca, Inc.
SAN CARLOS, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a...